- Home
- LXEH vs CMND Comparison
LXEH vs CMND Comparison
Compare LXEH & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- CMND
- Stock Information
- Founded
- LXEH 2001
- CMND 2017
- Country
- LXEH China
- CMND Canada
- Employees
- LXEH N/A
- CMND N/A
- Industry
- LXEH Other Consumer Services
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- CMND Health Care
- Exchange
- LXEH Nasdaq
- CMND Nasdaq
- Market Cap
- LXEH 25.1M
- CMND 4.8M
- IPO Year
- LXEH 2020
- CMND N/A
- Fundamental
- Price
- LXEH $1.36
- CMND $0.98
- Analyst Decision
- LXEH
- CMND
- Analyst Count
- LXEH 0
- CMND 0
- Target Price
- LXEH N/A
- CMND N/A
- AVG Volume (30 Days)
- LXEH 349.2K
- CMND 2.2M
- Earning Date
- LXEH 09-15-2025
- CMND 06-12-2025
- Dividend Yield
- LXEH N/A
- CMND N/A
- EPS Growth
- LXEH N/A
- CMND N/A
- EPS
- LXEH N/A
- CMND N/A
- Revenue
- LXEH $4,493,795.00
- CMND N/A
- Revenue This Year
- LXEH N/A
- CMND N/A
- Revenue Next Year
- LXEH N/A
- CMND N/A
- P/E Ratio
- LXEH N/A
- CMND N/A
- Revenue Growth
- LXEH N/A
- CMND N/A
- 52 Week Low
- LXEH $1.20
- CMND $0.80
- 52 Week High
- LXEH $50.08
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- LXEH 34.79
- CMND 54.57
- Support Level
- LXEH $1.23
- CMND $0.93
- Resistance Level
- LXEH $1.75
- CMND $1.00
- Average True Range (ATR)
- LXEH 0.20
- CMND 0.08
- MACD
- LXEH 0.10
- CMND 0.01
- Stochastic Oscillator
- LXEH 23.85
- CMND 30.35
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.